Your browser is no longer supported. Please, upgrade your browser.
Settings
ONCY [NASD]
Oncolytics Biotech Inc.
Index- P/E- EPS (ttm)-0.50 Insider Own1.80% Shs Outstand54.33M Perf Week6.97%
Market Cap120.12M Forward P/E- EPS next Y-0.30 Insider Trans0.00% Shs Float54.24M Perf Month-6.52%
Income-23.50M PEG- EPS next Q-0.11 Inst Own2.50% Short Float1.48% Perf Quarter-25.86%
Sales- P/S- EPS this Y62.70% Inst Trans48.47% Short Ratio3.84 Perf Half Y-41.89%
Book/sh0.67 P/B3.21 EPS next Y- ROA-67.60% Target Price- Perf Year31.10%
Cash/sh0.72 P/C3.00 EPS next 5Y- ROE-87.00% 52W Range1.56 - 4.83 Perf YTD-9.66%
Dividend- P/FCF- EPS past 5Y13.60% ROI- 52W High-55.49% Beta2.75
Dividend %- Quick Ratio21.50 Sales past 5Y- Gross Margin- 52W Low37.82% ATR0.10
Employees25 Current Ratio21.50 Sales Q/Q- Oper. Margin- RSI (14)48.96 Volatility4.60% 4.44%
OptionableNo Debt/Eq0.02 EPS Q/Q22.60% Profit Margin- Rel Volume0.54 Prev Close2.18
ShortableYes LT Debt/Eq0.01 EarningsAug 06 BMO Payout- Avg Volume209.17K Price2.15
Recom- SMA20-0.41% SMA50-3.11% SMA200-22.29% Volume112,871 Change-1.38%
Feb-17-21Initiated H.C. Wainwright Buy $15
Sep-20-21 08:00AM  
Sep-03-21 01:51PM  
Aug-18-21 10:00AM  
Aug-06-21 07:00AM  
07:00AM  
06:30AM  
06:30AM  
Jul-22-21 07:00AM  
07:00AM  
Jun-30-21 07:00AM  
07:00AM  
May-20-21 07:00AM  
07:00AM  
May-13-21 07:00AM  
07:00AM  
May-10-21 07:00AM  
07:00AM  
May-07-21 10:10AM  
07:00AM  
07:00AM  
Apr-30-21 07:00AM  
07:00AM  
Apr-29-21 07:00AM  
07:00AM  
Apr-14-21 05:37AM  
Apr-12-21 10:23AM  
07:02AM  
07:02AM  
07:00AM  
Apr-09-21 11:56AM  
11:52AM  
Apr-08-21 07:00AM  
07:00AM  
Apr-05-21 07:00AM  
Mar-25-21 08:44AM  
Mar-23-21 12:22PM  
Mar-10-21 04:32PM  
04:32PM  
Mar-05-21 07:32AM  
07:32AM  
07:30AM  
07:30AM  
06:30AM  
Mar-02-21 03:20PM  
Feb-26-21 07:00AM  
07:00AM  
Feb-23-21 07:00AM  
Feb-17-21 10:12AM  
10:07AM  
09:56AM  
Feb-08-21 08:00AM  
Jan-20-21 07:00AM  
Jan-13-21 08:00AM  
Dec-23-20 06:46AM  
Dec-11-20 12:57PM  
Dec-09-20 09:30AM  
09:30AM  
Nov-26-20 06:15PM  
Nov-19-20 09:05AM  
09:05AM  
Nov-17-20 09:05AM  
Nov-11-20 04:01PM  
04:01PM  
03:15PM  
Nov-09-20 07:05AM  
Nov-06-20 07:00AM  
Oct-27-20 07:00AM  
Oct-19-20 07:00AM  
07:00AM  
Oct-12-20 09:36AM  
Oct-07-20 07:00AM  
07:00AM  
Sep-01-20 09:25AM  
Aug-26-20 07:00AM  
07:00AM  
Aug-10-20 07:00AM  
Aug-04-20 04:01PM  
Jun-25-20 07:00AM  
07:00AM  
Jun-23-20 07:00AM  
07:00AM  
Jun-15-20 08:15PM  
Jun-04-20 07:00AM  
07:00AM  
May-29-20 07:00AM  
07:00AM  
May-26-20 07:00AM  
07:00AM  
May-18-20 02:47PM  
May-14-20 07:00AM  
07:00AM  
May-13-20 07:00AM  
07:00AM  
May-12-20 10:38AM  
May-08-20 07:00AM  
07:00AM  
May-05-20 03:11PM  
May-04-20 07:00AM  
Apr-30-20 07:00AM  
07:00AM  
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.